Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: A redox-dependent effect

Carcinogenesis

Volumn 30, Issue 3, 2009, Pages 512-519

  Zhao, Wenping ^a   Mackenzie, Gerardo G ^a   Murray, Onika T ^a   Zhang, Zhiquan ^a   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MDC 43; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOASPIRIN; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL KINETICS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; ASPIRIN; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; ISOMERISM; MEMBRANE POTENTIAL, MITOCHONDRIAL; OXIDATION-REDUCTION; PHOSPHORIC ACID ESTERS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 62349130701     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp015     Document Type: Article

References (36)

1. Baron,J.A. (2003) Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog. Exp. Tumor Res., 37, 1-24.
2. Baron,J.A. et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 348, 891-899.
3. Rayyan,Y. et al. (2002) The role of NSAIDs in the prevention of colon cancer. Cancer Invest., 20, 1002-1011.
4. Rigas,B. (2007) The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr. Opin. Gastroenterol., 23, 55-59.
5. Lazzarato,L. et al. (2008) Searching for new NO-donor aspirin-like molecules: A new class of nitrooxy-acyl derivatives of salicylic acid. J. Med. Chem., 51, 1894-1903.
6. Rigas,B. et al. (2008) The novel phenylester anticancer compounds: study of a derivative of aspirin (phoshoaspirin). Int. J. Oncol., 32, 97-100.
7. Kashfi,K. et al. (2005) Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J. Pharmacol. Exp. Ther., 312, 978-988.
8. Tietze,F. (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: Applications to mammalian blood and other tissues. Anal. Biochem., 27, 502-522.
9. Mackenzie,G.G. et al. (2004) Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-kappaB activation at multiple steps in Jurkat T cells. FASEB J., 18, 167-169.
10. Williams,J.L. et al. (2008) NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice. Carcinogenesis, 29, 390-397.
11. Williams,J.L. et al. (2001) Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: Implications for colon cancer chemoprevention. Cancer Res., 61, 3285-3289.
12. Rigas,B. et al. (2008) Induction of oxidative stress as a mechanism of action of chemopreventive agents against cancer. Br. J. Cancer, 98, 1157-1160.
13. LeBel,C.P. et al. (1992) Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol., 5, 227-231.
14. Meister,A. (1991) Glutathione deficiency produced by inhibition of its synthesis, and its reversal; applications in research and therapy. Pharmacol. Ther., 51, 155-194.
15. Klaunig,J.E. et al. (2004) The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 44, 239-267.
16. Griffith,O.W. et al. (1979) Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem., 254, 7558-7560.
17. Watson,A.J. (2004) Apoptosis and colorectal cancer. Gut, 53, 1701-1709.
18. Burgunder,J.M. et al. (1989) Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur. J. Clin. Pharmacol., 36, 127-131.
19. Pathak,S.K. et al. (2005) Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: Targets for chemopreventive strategies. Eur. J. Cancer, 41, 61-70.
20. Bubici,C. et al. (2006) The NF-kappaB-mediated control of ROS and JNK signaling. Histol. Histopathol., 21, 69-80.
21. Zhou,H. et al. (2009) Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling. Cancer Lett., 273, 292-299.
22. Mukhopadhyay,P. et al. (2007) Simultaneous detection of apoptosis and mitochondrial superoxide production in live cells by flow cytometry and confocal microscopy. Nat. Protoc., 2, 2295-2301.
23. Halliwell,B. (2007) Oxidative stress and cancer: Have we moved forward? Biochem. J., 401, 1-11.
24. Gao,J. et al. (2005) Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl Acad. Sci. USA, 102, 17207-17212.
25. Turjanski,A.G. et al. (2007) MAP kinases and the control of nuclear events. Oncogene, 26, 3240-3253.
26. Chang,L. et al. (2001) Mammalian MAP kinase signalling cascades. Nature, 410, 37-40.
27. Hundley,T.R. et al. (2006) Nitric oxide-donating aspirin inhibits colon cancer cell growth via mitogen-activated protein kinase activation. J. Pharmacol. Exp. Ther., 316, 25-34.
28. Manning,A.M. et al. (2003) Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov., 2, 554-565.
29. Pearson,G. et al. (2001) Mitogen-activated protein (MAP) kinase pathways: Regulation and physiological functions. Endocr. Rev., 22, 153-183.
30. Michl,P. et al. (2005) Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z. Gastroenterol., 43, 1133-1139.
31. Bode,A.M. et al. (2004) Targeting signal transduction pathways by chemopreventive agents. Mutat. Res., 555, 33-51.
32. Karin,M. et al. (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749-759.
33. Zhang,Z. et al. (2006) NF-kappaB, inflammation and pancreatic carcinogenesis: NF-kappaB as a chemoprevention target (review). Int. J. Oncol., 29, 185-192.
34. de Moraes,E. et al. (2007) Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis. Int. J. Cancer, 121, 929-937.
35. Sun,Y. et al. (2008) Chemopreventive agents induce oxidative stress in cancer cells leading to COX-2 overexpression and COX-2-independent cell death. Carcinogenesis, in press.
36. Sun,Y. et al. (2008) The thioredoxin system mediates redox-induced cell death in human colon cancer cells: Implications for the mechanism of action of anticancer agents. Cancer Res., 68, 8269-8277.